Your browser doesn't support javascript.
loading
TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.
Tricarico, Rossella; Madzo, Jozef; Scher, Gabrielle; Cohen, Maya; Jelinek, Jaroslav; Maegawa, Shinji; Nagarathinam, Rajeswari; Scher, Carly; Chang, Wen-Chi; Nicolas, Emmanuelle; Slifker, Michael; Zhou, Yan; Devarajan, Karthik; Cai, Kathy Q; Kwok, Tim; Nakajima, Pamela; Xu, Jinfei; Mancuso, Pietro; Doneddu, Valentina; Bagella, Luigi; Williams, Riley; Balachandran, Siddharth; Maskalenko, Nicholas; Campbell, Kerry; Ma, Xueying; Cañadas, Israel; Viana-Errasti, Julen; Moreno, Victor; Valle, Laura; Grivennikov, Sergei; Peshkova, Iuliia; Kurilenko, Natalia; Mazitova, Aleksandra; Koltsova, Ekaterina; Lee, Hayan; Walsh, Martin; Duttweiler, Reuben; Whetstine, Johnathan R; Yen, Timothy J; Issa, Jean-Pierre; Bellacosa, Alfonso.
Afiliação
  • Tricarico R; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Madzo J; Coriell Institute for Medical Research, Camden, New Jersey.
  • Scher G; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cohen M; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Jelinek J; Coriell Institute for Medical Research, Camden, New Jersey.
  • Maegawa S; University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Nagarathinam R; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Scher C; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Chang WC; Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nicolas E; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Slifker M; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Zhou Y; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Devarajan K; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cai KQ; Experimental Histopathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Kwok T; Cell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nakajima P; Cell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Xu J; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Mancuso P; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Doneddu V; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Bagella L; Department of Biomedical Sciences, University of Sassari, Sassari, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
  • Williams R; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Balachandran S; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Maskalenko N; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Campbell K; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Ma X; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cañadas I; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Viana-Errasti J; Hereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
  • Moreno V; Oncology Data Analytics Program, Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain; Department of Clinical Sciences, Faculty of
  • Valle L; Hereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Grivennikov S; Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Peshkova I; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Kurilenko N; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Mazitova A; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Koltsova E; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Lee H; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Walsh M; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Duttweiler R; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Whetstine JR; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Yen TJ; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Issa JP; Coriell Institute for Medical Research, Camden, New Jersey.
  • Bellacosa A; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: Alfonso.Bellacosa@fccc.edu.
Gastroenterology ; 164(6): 921-936.e1, 2023 05.
Article em En | MEDLINE | ID: mdl-36764492
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenocarcinoma / Adenoma / Neoplasias do Colo Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenocarcinoma / Adenoma / Neoplasias do Colo Idioma: En Ano de publicação: 2023 Tipo de documento: Article